Compliance

By Mark Land, M.S., RAC-US, AAHP President As we settle into 2025, opportunities should increase for natural products, including homeopathy, from a more favorable climate within government.   From Capitol…

Homeopathy, like all sectors of the healthcare industry, is subject to oversight and influence from various parts of the U.S. government. From Congress to regulatory agencies, different entities play a…

By Mark Land, M.S., RAC-US, AAHP President Monitoring and reporting on the safety of homeopathic drug products is a multifaceted undertaking that begins in the product development stage. Homeopathic drug…

By Robert Sven Jechlitschka, Director of Quality and Development, Schwabe Pharma México  In September 2024, the Food and Drug Administration published a final guidance document on Control of Nitrosamine Impurities…

By Eric L. Foxman, HPCUS Senior Scientist  While many might be familiar with the nomenclature and concept of “First Safe Dilution” (FSD), the Homeopathic Pharmacopeia Convention of the United States…

By Kristina Skowronek, Dir. of Quality and Regulatory Compliance, Boiron, Inc. The FDA Adverse Event Reporting System (FAERS) has a public dashboard online where healthcare practitioners, retailers, consumers, and industry…

By Alvin J. Lorman, AAHP Counsel The lawsuit filed last October challenging FDA’s characterization of homeopathic products as unapproved new drugs will not be decided before the second quarter of…

By Mark Land, M.S., RAC-US, AAHP President  To support the growth of member companies’ businesses and address issues in our new environment, the AAHP Board developed the following agenda built…

By Mark Land, M.S., RAC-US, AAHP President This year 2025 is poised to be one of the most dynamic years in recent memory. Everyone is aware by now of the…

By Mark Land, MS, RAC-US, AAHP President As 2024 comes to a close, let’s reflect on some of the news related to homeopathy and AAHP’s achievements. General News Affecting Homeopathy…